Scarica l'app Stockscreener
484.15
3.37%
15.77
Pre-mercato:
480.70
-3.45
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$468.38
Aprire:
$469.125
Volume 24 ore:
1.71M
Relative Volume:
1.28
Capitalizzazione di mercato:
$122.84B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
34.12
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+6.79%
1M Prestazione:
+6.29%
6M Prestazione:
+5.39%
1 anno Prestazione:
+18.57%
Intervallo 1D:
$467.46
$487.52
Intervallo di 1 settimana:
$443.12
$487.52
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Stock: Cost Of Growing Beyond Cystic Fibrosis (NASDAQ:VRTX) - Seeking Alpha
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga
‘We were sitting with our calculator saying “we can afford that!”’ Joy for families as cystic fibrosis drug prices fall within reach - The Guardian
Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies - The Globe and Mail
UBS Lowers Price Target for Vertex Pharmaceuticals (VRTX) to $53 - GuruFocus
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) to Outperf - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Outperform at Wolfe Research - MarketBeat
Wolfe Research Upgrades Vertex Pharmaceuticals to Outperform From Peer Perform, Price Target is $548 - MarketScreener
Robeco Institutional Asset Management B.V. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Advisory Resource Group Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
My 10 Top Stocks to Buy to Start the New Year Off Right - The Motley Fool
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Benzinga
5 Clinical Readouts to Watch in H1 2026 - BioSpace
Vertex Pharmaceuticals Incorporated $VRTX Position Increased by Asset Management One Co. Ltd. - MarketBeat
Aug Retail: Will Vertex Pharmaceuticals Incorporated VX1 stock test record highs in 2025Trade Volume Report & Verified Chart Pattern Signals - moha.gov.vn
Generali Asset Management SPA SGR Acquires 6,942 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Coastline Trust Co Sells 3,145 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks To Follow NowJanuary 1st - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Best Stocks to Invest $1,000 in to Start the New Year Off Right - Finviz
When Phase 3 Data Drops, What Determines A Sustained Rally Vs. A Fading Initial Pop - Benzinga
25,734 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Generate Investment Management Ltd - MarketBeat
Ethic Inc. Has $5.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - sharewise.com
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock - Nasdaq
2 Growth Stocks to Buy For 2026 and Beyond - Finviz
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink - Yahoo Finance
Orna Therapeutics collaborates with Vertex Pharmaceuticals to develop approaches for sickle cell disease - MSN
Leerink Partners Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $525.00 - MarketBeat
Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook? - Insider Monkey
Vertex Pharma’s Cystic Fibrosis Franchise: How Trikafta Powers the Pipeline — and the Stock - AD HOC NEWS
Biotech Stocks To Keep An Eye OnDecember 25th - MarketBeat
Burney Co. Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock: Biotech momentum meets Wall Street optimism - AD HOC NEWS
Forget Moderna Stock, This is a Much Better Buy - Finviz
Vertex Pharmaceuticals Earnings Notes - Trefis
Greenwood Capital Associates LLC Acquires 2,514 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Pacer Advisors Inc. Acquires 26,543 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Market Review: How analysts rate Vertex Pharmaceuticals Incorporated stock todayJuly 2025 Fed Impact & Long-Term Safe Investment Plans - moha.gov.vn
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? - MSN
Exchange Traded Concepts LLC Purchases 7,565 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Vontobel Holding Ltd. - MarketBeat
GLOBALT Investments LLC GA Has $1.87 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Leerink Partners Adjusts Price Target on Vertex Pharmaceuticals to $525 From $456 - marketscreener.com
Is CRISPR Therapeutics Stock Yesterday's News? - Finviz
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):